AcroBiosystems leans on overseas sales in renewed Hong Kong listing bid
The company leads the field for recombinant proteins among its domestic peers, but overseas companies dominate the international market Key Takeaways: AcroBiosystems has applied to list in Hong Kong, reporting…
WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
WuXi AppTec frees up money for Middle East push
The drugs services giant has stepped up sales of non-core Chinese assets to concentrate on its international expansion, with plans for a base in Saudi Arabia Key Takeaways: The company…
BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount
Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday announced two share placements to raise a combined HK$2.71 billion ($348 million) in new funds. The company plans to…
Recent Articles
WuXi AppTec wages buyback campaign as U.S. pressure mounts
2359.HK
603259.SHG
WuXi AppTec frees up money for Middle East push
2359.HK
603259.SHG
RELATED ARTICLES
-
Looking for overseas growth, Aier Eye seeks Hong Kong listing
300015.SHE -
Newborn Town leans on better monetization as user growth slows
9911.HK
- ESWIN Computing powers up its RISC-V growth story for Hong Kong investors
- Unsated by Hong Kong listing, Knowledge Atlas seeks more funds in Shanghai
-
Shantui Construction bulldozes its way towards Hong Kong listing
000680.SHE
- Fosun tries again with new Club Med Hong Kong IPO bid
- Avatr parks its NEV listing in Hong Kong, complete with losses and state ownership
